Research & Development

Morphic Therapeutic enters into integrin research and development collaboration with Janssen

Morphic Therapeutic, a biotechnology company developing oral integrin therapies, has entered into a research and development collaboration with Janssen Biotech, to discover and develop novel integrin therapeutics for patients with conditions not adequately addressed by current therapies.

Merck to buy late-stage immunotherapy firm Immune Design for $300m

Merck has signed an agreement to acquire late-stage immunotherapy firm, Immune Design, in a deal valued at around $300m.

Peloton Therapeutics secures $150m in Series E financing

Peloton Therapeutics, a drug discovery and development company advancing oral medicines for cancer and other serious conditions, has announced the closing of an oversubscribed $150 million Series E financing.

Knight Therapeutics signs Latin American funding deal with Moksha8

Knight Therapeutics, a Canadian specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative prescription pharmaceutical products and Moksha8, a specialty pharmaceutical company focused on licensing and marketing innovative and established therapeutics in Latin America, announced the closing of a strategic financing agreement for up to $125m.

Decipher announces research collaboration with Dendreon to identify genomic drivers of patient response to Sipuleucel-T

Decipher Biosciences (formerly GenomeDx) has announced a research collaboration with Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, to apply genomic tumor profiling using the Decipher assay and GRID software to identify prostate cancer patients on active surveillance who may benefit most from treatment with sipuleucel-T.

Artificial intelligence can predict survival of ovarian cancer patients

Researchers have created new machine learning software that can forecast the survival rates and response to treatments of patients with ovarian cancer.

Bayer gets full rights to Vitrakvi, LOXO-195 from Lilly’s Loxo Oncology

Bayer has obtained the full rights to global development and commercialization of Vitrakvi (larotrectinib) and BAY 2731954 (LOXO-195) from the US-based Loxo Oncology.

SK, Arvelle sign $530m deal for antiepileptic drug cenobamate

SK Biopharmaceuticals has entered into a $530m deal with the Arvelle Therapeutics for investigational antiepileptic drug cenobamate.

Vor Biopharma raises $42m to advance development of cell therapy product candidate for AML

Vor Biopharma, an immuno-oncology company pioneering engineered hematopoietic stem cell (HSC) therapies for the treatment of hematological malignancies, has announced a $42m Series A financing round led by 5AM Ventures and RA Capital Management.